The company’s R&D chief, Gregory Glenn, will present progress of COVID-19 vaccine candidate NVX-CoV2373 at 9:55 AM tomorrow at the 2nd International Society for Vaccines Virtual Congress.
The free webinar is here.
Novavax (NASDAQ:NVAX) fell 1.6% in the regular session today, but is up 8.6% after-hours on this news.
“We are United in our effort to defeat the Invisible China Virus, and many people say that it is Patriotic to wear a face mask when you can’t socially distance.” tweets the president. “There is nobody more Patriotic than me, your favorite President!”
Alpha Pro Tech (APT +9.2%), Allied Healthcare (AHPI +2.9%), Lakeland Industries (LAKE +1.1%).
A Phase 3 clinical trial, CLARITY, evaluating ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Nuplazid (pimavanserin) for the adjunctive treatment of major depressive disorder (MDD) failed to achieve the primary endpoint of a statistically significant change from baseline to week 5 in a scale called HAMD-17 compared to placebo.
Specifically, the mean reduction in HAMD-17 total score in the pimavanserin arm was 9.0 versus 8.1 in the control arm (p=0.296).
A key secondary endpoint, the change from baseline in a scale called CGI-1, was met (p=0.042), as was the change in Karolinska Sleepiness Scale (KSS) score.
No new safety signals were observed.
The company plans to combine the CLARITY-2 and CLARITY-3 trials. Both concluded with slightly greater than 50% enrollment.
The FDA approved pimavanserin, a non-dopaminergic antipsychotic, in April 2016 for Parkinson’s disease psychosis.
Management will host a conference call today at 4:30 pm ET to discuss the results.
OPKO Health’s (OPK +8.5%) BioReference Laboratories, an 11-lab network, has accepted a CDC contract to provide commercial surge capacity testing for COVID-19 emergency response to the CDC.
The agreement enables BioReference to perform antibody testing to determine the virus’ seroprevalence, and provide results with key demographic information and analysis in collaboration with the CDC.
The four-month contract started today.
The FDA has signed off on a Phase 2 clinical trial evaluating Sorrento Therapeutics’ (SRNE +17.0%) abivertinib, a small molecule tyrosine kinase inhibitor, in hospitalized COVID-19 patients who have moderate-to-severe pulmonary symptoms.
On another note, it has inked an agreement with Agilent (A +1.3%) unit ACEA Therapeutics for exclusive rights to abivertinib for all indications world-wide except China.
